English

Lotus Pharmaceuticals, Inc.

EDGAR

Quarterly report (10-Q) · filed 2011-11-10

34 filing records in this dataset, filed from 2005-06-10 to 2011-11-10. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

19 million USD

2011 Q3 · USD

Exact inputs and evidence

Revenue: 19044538 USD Source

Operating margin

6.66%

2011 Q3 · %

Exact inputs and evidence

Operating Income: 1268408 USD Source
Revenue: 19044538 USD Source

Operating cash flow

3.92 million USD

2011 Q3 · USD

Exact inputs and evidence

Operating Cash Flow: 10572259 USD Source
Operating Cash Flow: 6654189 USD Source

Cash and cash equivalents: 159 thousand USD 2011-09-30 Source
Exact value

158908 USD
Long-term debt including current maturities: Not available
Shares outstanding: 27.8 million shares 2011-09-30 Source
Exact value

27800927 shares

Trailing twelve months

The four most recent complete quarters added together. This gives a full-year view that includes the latest quarterly results.

Net income

1.74 million USD

2010-10-01 – 2011-09-30

Exact inputs and evidence

Net income: 14424943 USD · 2010-01-01 – 2010-12-31 Source
Net income: 17951106 USD · 2010-01-01 – 2010-09-30 Source
Net income: 2235084 USD · 2011-01-01 – 2011-03-31 Source
Net income: 1773771 USD · 2011-04-01 – 2011-06-30 Source
Net income: 1253341 USD · 2011-07-01 – 2011-09-30 Source

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2011-11-10.

Financial data available through: 2010-12-31.

Coverage by financial measure

Revenue: 6 of 11 periods available· newest 2010-12-31
Operating income: 6 of 11 periods available· newest 2010-12-31
Net income: 6 of 11 periods available· newest 2010-12-31
Operating cash flow: 6 of 11 periods available· newest 2010-12-31
Capital expenditure: 6 of 11 periods available· newest 2010-12-31
Total assets: 6 of 11 periods available· newest 2010-12-31
Total liabilities: 5 of 11 periods available· newest 2010-12-31
Current assets: 6 of 11 periods available· newest 2010-12-31
Current liabilities: 6 of 11 periods available· newest 2010-12-31
Cash and cash equivalents: 6 of 11 periods available· newest 2010-12-31
long term debt: No compatible figures in this window
Shares outstanding: 1 of 11 periods available· newest 2010-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Revenue
+28.7%

Prior period

USD 56.48 million

2009-01-01 – 2009-12-31
Current period

USD 72.7 million

2010-01-01 – 2010-12-31

Exact inputs and evidence

72696618 − 56482448 = 16214170 USD

56482448 USD · 2009-01-01 – 2009-12-31
Inspect prior input Prior source
72696618 USD · 2010-01-01 – 2010-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Revenue · Lotus Pharmaceuticals, Inc. · 2010-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Year-over-year change in Revenue: 16214170 USD Concept: fundies:Revenue Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:Revenue: 72696618 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#3896 Input fundies:Revenue: 56482448 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#3896
The citation records this snapshot. The page link may show a newer release later.
Net income
-12.2%

Prior period

USD 16.43 million

2009-01-01 – 2009-12-31
Current period

USD 14.42 million

2010-01-01 – 2010-12-31

Exact inputs and evidence

14424943 − 16432294 = -2007351 USD

16432294 USD · 2009-01-01 – 2009-12-31
Inspect prior input Prior source
14424943 USD · 2010-01-01 – 2010-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Lotus Pharmaceuticals, Inc. · 2010-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Year-over-year change in Net income: -2007351 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: 14424943 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4400 Input fundies:NetIncome: 16432294 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4400
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
-14.6%

Prior period

USD 31.36 million

2009-01-01 – 2009-12-31
Current period

USD 26.78 million

2010-01-01 – 2010-12-31

Exact inputs and evidence

26775776 − 31362466 = -4586690 USD

31362466 USD · 2009-01-01 – 2009-12-31
Inspect prior input Prior source
26775776 USD · 2010-01-01 – 2010-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Lotus Pharmaceuticals, Inc. · 2010-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Year-over-year change in Operating cash flow: -4586690 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: 26775776 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4532 Input fundies:OperatingCashFlow: 31362466 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4532
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
+164.9%

Prior period

USD 11.12 million

2009-01-01 – 2009-12-31
Current period

USD 29.45 million

2010-01-01 – 2010-12-31

Exact inputs and evidence

29448568 − 11118884 = 18329684 USD

11118884 USD · 2009-01-01 – 2009-12-31
Inspect prior input Prior source
29448568 USD · 2010-01-01 – 2010-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Lotus Pharmaceuticals, Inc. · 2010-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Year-over-year change in Capital expenditure: 18329684 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 29448568 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4545 Input fundies:CapitalExpenditure: 11118884 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4545
The citation records this snapshot. The page link may show a newer release later.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2010 2010-01-01 – 2010-12-31

Revenue USD 72.7 million 100% of revenue
Cost of revenue USD 32.92 million 45% of revenue
Operating expenses USD 25.26 million 35% of revenue
Operating income USD 14.52 million 20% of revenue
Tax, interest and other Derived USD 97,541 0.1% of revenue
Net income USD 14.42 million 20% of revenue

Cash

Operating cash flow USD 26.78 million 37% of revenue
Capital expenditure USD 29.45 million 41% of revenue
Free cash flow Derived −USD 2.67 million −3.7% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2005 Net income was higher than operating income, so the split is not drawn.
2006 11%88%
2007 20%80%
2008 17%80%
2009 29%68%
2010 20%80%

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2005 2005-01-01 – 2005-12-31	18345841	17733802 Derived	612039	-1219673 Derived	1831712	-2388490 Derived	Source 2005-01-01 – 2005-12-31: 18345841 USD Inspect Revenue Open source 2005-01-01 – 2005-12-31: 612039 USD Inspect Operating Income Open source 2005-01-01 – 2005-12-31: 1831712 USD Inspect Net Income Open source 2005-01-01 – 2005-12-31: -343280 USD Inspect Operating Cash Flow Open source 2005-01-01 – 2005-12-31: 2045210 USD Inspect Capital Expenditure Open source
2006 2006-01-01 – 2006-12-31	36207689	31738845 Derived	4468844	325824 Derived	4143020	4833162 Derived	Source 2006-01-01 – 2006-12-31: 36207689 USD Inspect Revenue Open source 2006-01-01 – 2006-12-31: 4468844 USD Inspect Operating Income Open source 2006-01-01 – 2006-12-31: 4143020 USD Inspect Net Income Open source 2006-01-01 – 2006-12-31: 4834642 USD Inspect Operating Cash Flow Open source 2006-01-01 – 2006-12-31: 1480 USD Inspect Capital Expenditure Open source
2007 2007-01-01 – 2007-12-31	56873115	45564822 Derived	11308293	91165 Derived	11217128	-1232227 Derived	Source 2007-01-01 – 2007-12-31: 56873115 USD Inspect Revenue Open source 2007-01-01 – 2007-12-31: 11308293 USD Inspect Operating Income Open source 2007-01-01 – 2007-12-31: 11217128 USD Inspect Net Income Open source 2007-01-01 – 2007-12-31: -850455 USD Inspect Operating Cash Flow Open source 2007-01-01 – 2007-12-31: 381772 USD Inspect Capital Expenditure Open source
2008 2008-01-01 – 2008-12-31	73803029	58733085 Derived	15069944	2279296 Derived	12790648	35955665 Derived	Source 2008-01-01 – 2008-12-31: 73803029 USD Inspect Revenue Open source 2008-01-01 – 2008-12-31: 15069944 USD Inspect Operating Income Open source 2008-01-01 – 2008-12-31: 12790648 USD Inspect Net Income Open source 2008-01-01 – 2008-12-31: 37394084 USD Inspect Operating Cash Flow Open source 2008-01-01 – 2008-12-31: 1438419 USD Inspect Capital Expenditure Open source
2009 2009-01-01 – 2009-12-31	56482448	38505634 Derived	17976814	1544520 Derived	16432294	20243582 Derived	Source 2009-01-01 – 2009-12-31: 56482448 USD Inspect Revenue Open source 2009-01-01 – 2009-12-31: 17976814 USD Inspect Operating Income Open source 2009-01-01 – 2009-12-31: 16432294 USD Inspect Net Income Open source 2009-01-01 – 2009-12-31: 31362466 USD Inspect Operating Cash Flow Open source 2009-01-01 – 2009-12-31: 11118884 USD Inspect Capital Expenditure Open source
2010 2010-01-01 – 2010-12-31	72696618	58174134 Derived	14522484	97541 Derived	14424943	-2672792 Derived	Source 2010-01-01 – 2010-12-31: 72696618 USD Inspect Revenue Open source 2010-01-01 – 2010-12-31: 14522484 USD Inspect Operating Income Open source 2010-01-01 – 2010-12-31: 14424943 USD Inspect Net Income Open source 2010-01-01 – 2010-12-31: 26775776 USD Inspect Operating Cash Flow Open source 2010-01-01 – 2010-12-31: 29448568 USD Inspect Capital Expenditure Open source

Amounts are exact, in USD.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

USD 72.7M 2010

Values and sources

Revenue values and source evidence
Period	Series	Value(USD)	Source evidence
20052005-12-31	Revenue	18345841	Revenue: 18345841 Open source
20062006-12-31	Revenue	36207689	Revenue: 36207689 Open source
20072007-12-31	Revenue	56873115	Revenue: 56873115 Open source
20082008-12-31	Revenue	73803029	Revenue: 73803029 Open source
20092009-12-31	Revenue	56482448	Revenue: 56482448 Open source
20102010-12-31	Revenue	72696618	Revenue: 72696618 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

28.7% 2010

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20052005-12-31	Year over year	No prior comparable period	Revenue: 18345841 Open source
20062006-12-31	Year over year	97.4%	Revenue: 36207689 Open source Revenue: 18345841 Open source
20072007-12-31	Year over year	57.1%	Revenue: 56873115 Open source Revenue: 36207689 Open source
20082008-12-31	Year over year	29.8%	Revenue: 73803029 Open source Revenue: 56873115 Open source
20092009-12-31	Year over year	-23.5%	Revenue: 56482448 Open source Revenue: 73803029 Open source
20102010-12-31	Year over year	28.7%	Revenue: 72696618 Open source Revenue: 56482448 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin 20% 2010

Net margin 19.8% 2010

Free cash flow margin -3.7% 2010

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20052005-12-31	Operating margin	3.3%	Operating Income: 612039 Open source Revenue: 18345841 Open source
20062006-12-31	Operating margin	12.3%	Operating Income: 4468844 Open source Revenue: 36207689 Open source
20072007-12-31	Operating margin	19.9%	Operating Income: 11308293 Open source Revenue: 56873115 Open source
20082008-12-31	Operating margin	20.4%	Operating Income: 15069944 Open source Revenue: 73803029 Open source
20092009-12-31	Operating margin	31.8%	Operating Income: 17976814 Open source Revenue: 56482448 Open source
20102010-12-31	Operating margin	20%	Operating Income: 14522484 Open source Revenue: 72696618 Open source
20052005-12-31	Net margin	10%	Net Income: 1831712 Open source Revenue: 18345841 Open source
20062006-12-31	Net margin	11.4%	Net Income: 4143020 Open source Revenue: 36207689 Open source
20072007-12-31	Net margin	19.7%	Net Income: 11217128 Open source Revenue: 56873115 Open source
20082008-12-31	Net margin	17.3%	Net Income: 12790648 Open source Revenue: 73803029 Open source
20092009-12-31	Net margin	29.1%	Net Income: 16432294 Open source Revenue: 56482448 Open source
20102010-12-31	Net margin	19.8%	Net Income: 14424943 Open source Revenue: 72696618 Open source
20052005-12-31	Free cash flow margin	-13%	Revenue: 18345841 Open source Operating Cash Flow: -343280 Open source Capital Expenditure: 2045210 Open source
20062006-12-31	Free cash flow margin	13.3%	Revenue: 36207689 Open source Operating Cash Flow: 4834642 Open source Capital Expenditure: 1480 Open source
20072007-12-31	Free cash flow margin	-2.2%	Revenue: 56873115 Open source Operating Cash Flow: -850455 Open source Capital Expenditure: 381772 Open source
20082008-12-31	Free cash flow margin	48.7%	Revenue: 73803029 Open source Operating Cash Flow: 37394084 Open source Capital Expenditure: 1438419 Open source
20092009-12-31	Free cash flow margin	35.8%	Revenue: 56482448 Open source Operating Cash Flow: 31362466 Open source Capital Expenditure: 11118884 Open source
20102010-12-31	Free cash flow margin	-3.7%	Revenue: 72696618 Open source Operating Cash Flow: 26775776 Open source Capital Expenditure: 29448568 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

USD 26.8M 2010

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20052005-12-31	Operating cash flow	-343280	Operating Cash Flow: -343280 Open source
20062006-12-31	Operating cash flow	4834642	Operating Cash Flow: 4834642 Open source
20072007-12-31	Operating cash flow	-850455	Operating Cash Flow: -850455 Open source
20082008-12-31	Operating cash flow	37394084	Operating Cash Flow: 37394084 Open source
20092009-12-31	Operating cash flow	31362466	Operating Cash Flow: 31362466 Open source
20102010-12-31	Operating cash flow	26775776	Operating Cash Flow: 26775776 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

USD -2.7M 2010

Values and sources

Free cash flow values and source evidence
Period	Series	Value(USD)	Source evidence
20052005-12-31	Free cash flow	-2388490	Operating Cash Flow: -343280 Open source Capital Expenditure: 2045210 Open source
20062006-12-31	Free cash flow	4833162	Operating Cash Flow: 4834642 Open source Capital Expenditure: 1480 Open source
20072007-12-31	Free cash flow	-1232227	Operating Cash Flow: -850455 Open source Capital Expenditure: 381772 Open source
20082008-12-31	Free cash flow	35955665	Operating Cash Flow: 37394084 Open source Capital Expenditure: 1438419 Open source
20092009-12-31	Free cash flow	20243582	Operating Cash Flow: 31362466 Open source Capital Expenditure: 11118884 Open source
20102010-12-31	Free cash flow	-2672792	Operating Cash Flow: 26775776 Open source Capital Expenditure: 29448568 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

13.7% 2010

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2005-12-31	Liabilities / assets	Not reported	Total Assets: 85296 Open source
20062006-12-31	Liabilities / assets	45.7%	Total Liabilities: 9929507 Open source Total Assets: 21737605 Open source
20072007-12-31	Liabilities / assets	27.8%	Total Liabilities: 10262916 Open source Total Assets: 36899533 Open source
20082008-12-31	Liabilities / assets	29.2%	Total Liabilities: 18574408 Open source Total Assets: 63708518 Open source
20092009-12-31	Liabilities / assets	22%	Total Liabilities: 18582709 Open source Total Assets: 84380935 Open source
20102010-12-31	Liabilities / assets	13.7%	Total Liabilities: 14161574 Open source Total Assets: 103184615 Open source

Current assets to current liabilities

Current assets divided by current liabilities.

0.56× 2010

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
20052005-12-31	Current assets / current liabilities	0.84×	Current Assets: 68269 Open source Current Liabilities: 80937 Open source
20062006-12-31	Current assets / current liabilities	2.94×	Current Assets: 12752003 Open source Current Liabilities: 4336180 Open source
20072007-12-31	Current assets / current liabilities	6.15×	Current Assets: 29438245 Open source Current Liabilities: 4786108 Open source
20082008-12-31	Current assets / current liabilities	1.53×	Current Assets: 13762574 Open source Current Liabilities: 8976041 Open source
20092009-12-31	Current assets / current liabilities	0.61×	Current Assets: 7694850 Open source Current Liabilities: 12647584 Open source
20102010-12-31	Current assets / current liabilities	0.56×	Current Assets: 4541464 Open source Current Liabilities: 8050678 Open source

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2005 2005-01-01 – 2005-12-31	USD 1.83 million Exact value Exact value: 1831712 USD 2005-01-01 – 2005-12-31: 1831712 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lotus Pharmaceuticals, Inc. · 2005-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Net Income: 1831712 USD Concept: fundies:NetIncome Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ANetIncome&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:NetIncome: 1831712 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-08-000166.txt#8290 The citation records this snapshot. The page link may show a newer release later.	−USD 343,280 Exact value Exact value: -343280 USD 2005-01-01 – 2005-12-31: -343280 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lotus Pharmaceuticals, Inc. · 2005-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Operating Cash Flow: -343280 USD Concept: fundies:OperatingCashFlow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3AOperatingCashFlow&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -343280 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001144204-07-019181.txt#12296 The citation records this snapshot. The page link may show a newer release later.	USD 2.05 million Exact value Exact value: 2045210 USD 2005-01-01 – 2005-12-31: 2045210 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lotus Pharmaceuticals, Inc. · 2005-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Capital Expenditure: 2045210 USD Concept: fundies:CapitalExpenditure Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ACapitalExpenditure&period=2005-12-31&surface=latest&period_type=duration&start=2005-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 2045210 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001144204-07-019181.txt#12357 The citation records this snapshot. The page link may show a newer release later.	−USD 2.39 million Calculation and evidence -343280 − 2045210 USD Exact free cash flow: -2388490 USD 2005-01-01 – 2005-12-31: -343280 USD · Inspect Operating Cash Flow · Source 2005-01-01 – 2005-12-31: 2045210 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lotus Pharmaceuticals, Inc. · 2005-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Free cash flow: -2388490 USD Concept: free-cash-flow Period: 2005-01-01 to 2005-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -343280 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001144204-07-019181.txt#12296 Input fundies:CapitalExpenditure: 2045210 USD (2005-01-01 to 2005-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001144204-07-019181.txt#12357 The citation records this snapshot. The page link may show a newer release later.
2006 2006-01-01 – 2006-12-31	USD 4.14 million Exact value Exact value: 4143020 USD 2006-01-01 – 2006-12-31: 4143020 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lotus Pharmaceuticals, Inc. · 2006-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Net Income: 4143020 USD Concept: fundies:NetIncome Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ANetIncome&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:NetIncome: 4143020 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-08-000402.txt#3940 The citation records this snapshot. The page link may show a newer release later.	USD 4.83 million Exact value Exact value: 4834642 USD 2006-01-01 – 2006-12-31: 4834642 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lotus Pharmaceuticals, Inc. · 2006-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Operating Cash Flow: 4834642 USD Concept: fundies:OperatingCashFlow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3AOperatingCashFlow&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 4834642 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-08-000402.txt#3959 The citation records this snapshot. The page link may show a newer release later.	USD 1,480 Exact value Exact value: 1480 USD 2006-01-01 – 2006-12-31: 1480 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lotus Pharmaceuticals, Inc. · 2006-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Capital Expenditure: 1480 USD Concept: fundies:CapitalExpenditure Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ACapitalExpenditure&period=2006-12-31&surface=latest&period_type=duration&start=2006-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1480 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-08-000402.txt#3963 The citation records this snapshot. The page link may show a newer release later.	USD 4.83 million Calculation and evidence 4834642 − 1480 USD Exact free cash flow: 4833162 USD 2006-01-01 – 2006-12-31: 4834642 USD · Inspect Operating Cash Flow · Source 2006-01-01 – 2006-12-31: 1480 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lotus Pharmaceuticals, Inc. · 2006-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Free cash flow: 4833162 USD Concept: free-cash-flow Period: 2006-01-01 to 2006-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 4834642 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-08-000402.txt#3959 Input fundies:CapitalExpenditure: 1480 USD (2006-01-01 to 2006-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-08-000402.txt#3963 The citation records this snapshot. The page link may show a newer release later.
2007 2007-01-01 – 2007-12-31	USD 11.22 million Exact value Exact value: 11217128 USD 2007-01-01 – 2007-12-31: 11217128 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lotus Pharmaceuticals, Inc. · 2007-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Net Income: 11217128 USD Concept: fundies:NetIncome Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ANetIncome&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:NetIncome: 11217128 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001144204-09-020820.txt#12926 The citation records this snapshot. The page link may show a newer release later.	−USD 850,455 Exact value Exact value: -850455 USD 2007-01-01 – 2007-12-31: -850455 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lotus Pharmaceuticals, Inc. · 2007-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Operating Cash Flow: -850455 USD Concept: fundies:OperatingCashFlow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3AOperatingCashFlow&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: -850455 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001144204-09-020820.txt#13203 The citation records this snapshot. The page link may show a newer release later.	USD 381,772 Exact value Exact value: 381772 USD 2007-01-01 – 2007-12-31: 381772 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lotus Pharmaceuticals, Inc. · 2007-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Capital Expenditure: 381772 USD Concept: fundies:CapitalExpenditure Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ACapitalExpenditure&period=2007-12-31&surface=latest&period_type=duration&start=2007-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 381772 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001144204-09-020820.txt#13285 The citation records this snapshot. The page link may show a newer release later.	−USD 1.23 million Calculation and evidence -850455 − 381772 USD Exact free cash flow: -1232227 USD 2007-01-01 – 2007-12-31: -850455 USD · Inspect Operating Cash Flow · Source 2007-01-01 – 2007-12-31: 381772 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lotus Pharmaceuticals, Inc. · 2007-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Free cash flow: -1232227 USD Concept: free-cash-flow Period: 2007-01-01 to 2007-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -850455 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001144204-09-020820.txt#13203 Input fundies:CapitalExpenditure: 381772 USD (2007-01-01 to 2007-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001144204-09-020820.txt#13285 The citation records this snapshot. The page link may show a newer release later.
2008 2008-01-01 – 2008-12-31	USD 12.79 million Exact value Exact value: 12790648 USD 2008-01-01 – 2008-12-31: 12790648 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lotus Pharmaceuticals, Inc. · 2008-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Net Income: 12790648 USD Concept: fundies:NetIncome Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ANetIncome&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:NetIncome: 12790648 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-10-000280.txt#11434 The citation records this snapshot. The page link may show a newer release later.	USD 37.39 million Exact value Exact value: 37394084 USD 2008-01-01 – 2008-12-31: 37394084 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lotus Pharmaceuticals, Inc. · 2008-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Operating Cash Flow: 37394084 USD Concept: fundies:OperatingCashFlow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3AOperatingCashFlow&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 37394084 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-10-000280.txt#11808 The citation records this snapshot. The page link may show a newer release later.	USD 1.44 million Exact value Exact value: 1438419 USD 2008-01-01 – 2008-12-31: 1438419 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lotus Pharmaceuticals, Inc. · 2008-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Capital Expenditure: 1438419 USD Concept: fundies:CapitalExpenditure Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ACapitalExpenditure&period=2008-12-31&surface=latest&period_type=duration&start=2008-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 1438419 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-10-000280.txt#11910 The citation records this snapshot. The page link may show a newer release later.	USD 35.96 million Calculation and evidence 37394084 − 1438419 USD Exact free cash flow: 35955665 USD 2008-01-01 – 2008-12-31: 37394084 USD · Inspect Operating Cash Flow · Source 2008-01-01 – 2008-12-31: 1438419 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lotus Pharmaceuticals, Inc. · 2008-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Free cash flow: 35955665 USD Concept: free-cash-flow Period: 2008-01-01 to 2008-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 37394084 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-10-000280.txt#11808 Input fundies:CapitalExpenditure: 1438419 USD (2008-01-01 to 2008-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-10-000280.txt#11910 The citation records this snapshot. The page link may show a newer release later.
2009 2009-01-01 – 2009-12-31	USD 16.43 million Exact value Exact value: 16432294 USD 2009-01-01 – 2009-12-31: 16432294 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lotus Pharmaceuticals, Inc. · 2009-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Net Income: 16432294 USD Concept: fundies:NetIncome Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ANetIncome&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:NetIncome: 16432294 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4400 The citation records this snapshot. The page link may show a newer release later.	USD 31.36 million Exact value Exact value: 31362466 USD 2009-01-01 – 2009-12-31: 31362466 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lotus Pharmaceuticals, Inc. · 2009-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Operating Cash Flow: 31362466 USD Concept: fundies:OperatingCashFlow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3AOperatingCashFlow&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 31362466 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4532 The citation records this snapshot. The page link may show a newer release later.	USD 11.12 million Exact value Exact value: 11118884 USD 2009-01-01 – 2009-12-31: 11118884 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lotus Pharmaceuticals, Inc. · 2009-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Capital Expenditure: 11118884 USD Concept: fundies:CapitalExpenditure Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ACapitalExpenditure&period=2009-12-31&surface=latest&period_type=duration&start=2009-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 11118884 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4545 The citation records this snapshot. The page link may show a newer release later.	USD 20.24 million Calculation and evidence 31362466 − 11118884 USD Exact free cash flow: 20243582 USD 2009-01-01 – 2009-12-31: 31362466 USD · Inspect Operating Cash Flow · Source 2009-01-01 – 2009-12-31: 11118884 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lotus Pharmaceuticals, Inc. · 2009-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Free cash flow: 20243582 USD Concept: free-cash-flow Period: 2009-01-01 to 2009-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 31362466 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4532 Input fundies:CapitalExpenditure: 11118884 USD (2009-01-01 to 2009-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4545 The citation records this snapshot. The page link may show a newer release later.
2010 2010-01-01 – 2010-12-31	USD 14.42 million Exact value Exact value: 14424943 USD 2010-01-01 – 2010-12-31: 14424943 USD Inspect Net Income Open source Share or cite Citation for Net Income · Lotus Pharmaceuticals, Inc. · 2010-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Net Income: 14424943 USD Concept: fundies:NetIncome Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ANetIncome&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:NetIncome: 14424943 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4400 The citation records this snapshot. The page link may show a newer release later.	USD 26.78 million Exact value Exact value: 26775776 USD 2010-01-01 – 2010-12-31: 26775776 USD Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Lotus Pharmaceuticals, Inc. · 2010-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Operating Cash Flow: 26775776 USD Concept: fundies:OperatingCashFlow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3AOperatingCashFlow&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:OperatingCashFlow: 26775776 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4532 The citation records this snapshot. The page link may show a newer release later.	USD 29.45 million Exact value Exact value: 29448568 USD 2010-01-01 – 2010-12-31: 29448568 USD Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Lotus Pharmaceuticals, Inc. · 2010-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Capital Expenditure: 29448568 USD Concept: fundies:CapitalExpenditure Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087/explain?concept=fundies%3ACapitalExpenditure&period=2010-12-31&surface=latest&period_type=duration&start=2010-01-01&unit=USD&dimensions= Input fundies:CapitalExpenditure: 29448568 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4545 The citation records this snapshot. The page link may show a newer release later.	−USD 2.67 million Calculation and evidence 26775776 − 29448568 USD Exact free cash flow: -2672792 USD 2010-01-01 – 2010-12-31: 26775776 USD · Inspect Operating Cash Flow · Source 2010-01-01 – 2010-12-31: 29448568 USD · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Lotus Pharmaceuticals, Inc. · 2010-12-31 Lotus Pharmaceuticals, Inc. (edgar:1292087) Free cash flow: -2672792 USD Concept: free-cash-flow Period: 2010-01-01 to 2010-12-31 Values: Latest reported Published: 2026-11-02T16:29:15Z Snapshot: b0d15496eb0891549b8d18627b24ad82cba2d3cfbda5a078bab137f134254e7e Dimensions: Consolidated View: https://fundies.io/companies/edgar/1292087?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: 26775776 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4532 Input fundies:CapitalExpenditure: 29448568 USD (2010-01-01 to 2010-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1292087/0001161697-11-000268.txt#4545 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

34 filings · 277 latest values · 277 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001292087, 1292087, edgar:1292087, ltus

Also known as Lotus Pharmaceuticals, Inc., S.E. ASIA TRADING COMPANY, INC.

Lotus Pharmaceuticals, Inc.

Latest quarter

Revenue

Operating margin

Operating cash flow

Trailing twelve months

Net income

Company performance

What changed year over year

Revenue

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2010 2010-01-01 – 2010-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation